Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs. For more information, visit www.ascidian-tx.com.

Apple Tree Partners

Ascidian Therapeutics

"We’re just at the tip of the iceberg for what RNA exon editing can accomplish to address many of the underlying medical needs that exist..."

Our head of research, Robert Bell, spoke with Sarah Anderson of Drug Discovery News. Check it out here! 👇 

https://lnkd.in/efM_Wsaq

What an honor to be among these champions of science & advocacy at this year’s Investing in Cures Summit. 🌟 

Thank you to the Foundation Fighting Blindness & RD Fund for building a community of researchers, clinicians, patients & caregivers who are collaborating to speed new therapies & cures to people affected by retinal degenerative diseases.
 
Featured: Panel discussion on "Genetic Therapies: Exciting Innovations, Expanding Opportunities" with speakers Robert Bell of Ascidian Therapeutics, Shannon Boye of Atsena Therapeutics, Moderator Christine Kay, and Ben Yerxa of Opus Genetics.

#ICS2023 | Daniel Rosan, Carrie Wager

We're proud to be the women of Ascidian, driving our RNA exon editing science forward for patients awaiting breakthroughs. Today, our entire team supports the United Nations International Day of Women and Girls in Science and we are encouraged and inspired by all the girls who will drive the scientific innovations of tomorrow! 👩🔬 🔬
 
#WomenInScience #WIS2023 #IDWGIS #STEM

Thank you Keystone Symposia on Molecular & Cellular Biology for convening the global life sciences community this week in Colorado to share the groundbreaking research accelerating medical innovation.

#TeamAscidian's Robert Bell was honored to share the potential of RNA #ExonEditing therapies to treat rare diseases of the eye & CNS.

👇 Check out the full agenda!
https://lnkd.in/ep2udhmJ

#KSBrainDrugs23 | Robert Thorne | Leslie Dan Faculty of Pharmacy, University of Toronto

Happy #LunarNewYear from #TeamAscidian! We're celebrating with our team today & wish everyone joy, hope, peace & good health as we transition into the year of the Rabbit! 🐇

Ascidian is growing! Check out one of our new openings

As we close out a great week in San Francisco at #JPM23,  WuXi AppTec Global Forum & partner meetups, #TeamAscidian's Head of Research Robert Bell shares his Top 3 Takeaways on the week 👇 

🚀 Strong momentum behind RNA Therapies
🤝 Convergence & collaboration
👩🔬  Holistic approach to drug development

Romesh Subramanian Daniel Rosan | #RewritingRNA

“I see RNA being the molecule of the year.”

...Ascidian CEO Romesh Subramanian in discussion with Nina Kjellson from Canaan, on the outlook for scientific innovation & RNA’s tremendous potential for accelerating novel therapies to patients.
WuXi AppTec Global Forum #JPM23

This week, we're going with the flow 🌊. Our CEO, Romesh Subramanian, just presented as part of the #JPM23 private company track & is now on his way to participate in WuXi AppTec Global Forum's #BOLD panel on #RNATherapeutics.
 
Interested in our Ascidian story? Request our JPM presentation here!
👉 https://lnkd.in/gkH56-c9

We bet we aren't the only ones doing the pre-JPM travel essentials check! Here's what we're packing:

✅ Tech gear 👨💻📱 
✅ Business cards 👍 
✅ Healthy snacks 😋 
✅ Bomb cyclone rain gear 🌀☔
✅ Covid test & masks 😷 

We can't wait to connect IRL with colleagues & friends in SF & wish everyone safe travels 🛫🚗🛶! #JPM23 #TeamAscidian

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ASCIDIAN-TX

Ascidian Therapeutics